Crohn'
Conditions
Interventions
treatment with high dose infliximab and azathiopurine(6MP can be used in case of refractory patients to azatioupurine)
treatment with only high dose infliximab
Sponsors
Saitama Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients who had not been treated with immunomodulators and was not in remission state with low dose infliximab (CDAI<150)
Exclusion criteria
Exclusion criteria: patients who cannot been kept in the treatment with infliximab and who cannot been treated with azathiopurine patients in lactate state patient whose age below 15 years old and above 70 years old patients who cannot agree with this study patients who had been treated with open surgery within 6 months patients with short bowel syndrome patients who was determined not to be appropriate in participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission rate in 24 week | — |
Secondary
| Measure | Time frame |
|---|---|
| Remission rates in each state CR70, CR100 Mucosal healing rates in 24, 48 week Loss of response rate Relapse rate Safety | — |
Countries
Japan
Contacts
Public ContactShingo Kato
Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology
Outcome results
None listed